| 08.08 10:40 | Evotec erhält 25 Mio USD von Bristol Myers Squibb in Partnerschaft |
| 08.08 08:21 | dpa-AFX: Evotec Announces Progress In Strategic Neuroscience Collaboration With Bristol Myers Squibb |
| 08.08 07:38 | dpa-AFX: *EVOTEC ANNOUNCES PROGRESS IN STRATEGIC NEUROSCIENCE PARTNERSHIP WITH BRISTOL MYERS SQUIBB |
| 08.08 07:31 | dpa-AFX: *EVOTEC: PIPELINE-ZAHLUNG 25 MIO USD |
| 08.08 07:31 | dpa-AFX: *EVOTEC: FORTSCHRITT IN STRATEGISCHER NEUROLOGIE-PARTNERSCHAFT MIT BMS |
| 29.07 17:02 | dpa-AFX: *DZ BANK HEBT FAIREN WERT FÜR BRISTOL-MYERS SQUIBB AUF 56 (50) USD - 'KAUFEN' |
| 29.07 17:02 | dpa-AFX: *DZ BANK RAISES FAIR VALUE FOR BRISTOL-MYERS SQUIBB TO 56 (50) USD - 'BUY' |
| 29.07 12:47 | dpa-AFX: ANALYSE-FLASH: Barclays senkt Bristol-Myers Squibb auf 'Underweight' |
| 29.07 12:31 | dpa-AFX: *BARCLAYS CUTS BRISTOL-MYERS SQUIBB TO 'UNDERWEIGHT' (EQUAL W,) - PRICE TARGET 41 USD |
| 29.07 12:31 | dpa-AFX: *BARCLAYS SENKT BRISTOL-MYERS SQUIBB AUF 'UNDERWEIGHT' (EQUAL W.) - ZIEL 41 USD |
| 26.07 15:42 | dpa-AFX: *BRISTOL-MYERS SQUIBB +8,8% - ERHÖHT GEWINNAUSBLICK FÜR 2024 |
| 26.07 13:35 | dpa-AFX: Bristol Myers Squibb Raises 2024 Non-GAAP Guidance |
| 26.07 13:10 | dpa-AFX: *BRISTOL MYERS SQUIBB NOW EXPECTS FY24 NON-GAAP EPS OF $0.60 - $0.90 |
| 26.07 13:09 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 TOTAL REVENUES $12.201 BLN VS. $11.226 BLN LAST YEAR |
| 26.07 13:08 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 NET INCOME $1.680 BLN VS. $2.073 BLN LAST YEAR |
| 26.07 13:08 | dpa-AFX: Bristol-Myers Squibb Co. Q2 Profit Decreases, But Beats Estimates |
| 26.07 13:08 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 NON-GAAP EPS $2.07 VS. $1.75 LAST YEAR |
| 26.07 13:03 | dpa-AFX: *BRISTOL MYERS SQUIBB Q2 EPS $0.83 VS. $0.99 LAST YEAR |
| 26.07 12:00 | dpa-AFX: Bristol-Myers Squibb Q2 24 Earnings Conference Call At 8:00 AM ET |
| 19.07 13:53 | dpa-AFX: Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy For Treatment Of HCC |
|
|
